Merck Aims to Extend Winning Streak as Q4 Earnings Loom, Shares Up 13% in Past Year
Merck & Co. is set to report fourth-quarter 2025 results before the bell on Tuesday, with Wall Street anticipating steady growth. The pharmaceutical giant's shares have climbed 13% over the past year, outpacing the broader healthcare sector. All eyes will be on Keytruda's sales trajectory and management's guidance for the year ahead.